FUSE vs MyOrbitHealth: Which White-Label Platform Fits You

TLDR

FUSE vs MyOrbitHealth comes down to one question: are you launching a focused peptide, GLP-1 or longevity brand, or a broad multi-specialty clinic? FUSE publishes its prices (from $499/mo) and is built for how peptides sell. MyOrbit runs a wider, multi-specialty platform and quotes you after a demo.

Executive Summary

If you're weighing FUSE against MyOrbitHealth, you're really deciding between a peptide-native launchpad and a broad, multi-specialty telehealth backend. Both let you run a licensed clinic under your own brand with no medical license of your own, both cover all 50 states, and both handle prescribing, pharmacy, and compliance behind the scenes. The real gap shows up in two places an operator feels fast. FUSE publishes its prices out loud, from $499 a month, while MyOrbit asks you to book a call for a scoped quote. And FUSE is built around how peptide and GLP-1 brands actually sell, where MyOrbit spreads across 38+ specialties. If a focused peptide, GLP-1, or longevity brand is what you're launching, FUSE is the tighter fit. Here's the full picture, pulled straight from both companies' live pages.

What do FUSE and MyOrbitHealth actually do?

Both companies sell the same basic promise. You bring the brand and the audience, they run the regulated clinical machine underneath. Your customer sees your logo at checkout, while a licensed provider, a compliant pharmacy, and all the paperwork sit quietly on the platform. That's the white-label model in a sentence. Where the two split is who they're built for.

Who is MyOrbitHealth built for?

MyOrbit (you'll also see it searched as Orbit Health or Orbit Healthcare) pitches itself as telemedicine infrastructure for the next generation of digital clinics. Its own homepage lists customers across healthcare apps, med spas, brick-and-mortar clinics, insurers, e-commerce brands, gyms, and employers. That's a wide net, and the product stack is built to match: OrbitOS as the admin console, Orbit Intake for adaptive questionnaires, OrbitRx for e-prescribing, Orbit Labs for bloodwork, and a provider network the site puts at 2,400+ clinicians across 38+ specialties. If you want one backend that can run dermatology, hormones, weight loss, and sexual health all at once, that breadth is the whole appeal.

Where does FUSE focus?

FUSE narrows the aim on purpose. The tagline says it plainly: Shopify for peptides. Everything is tuned for operators launching peptide, GLP-1, and longevity programs, from the intake flow to the refill logic to the 503A/503B compounding pharmacy sourcing those programs depend on. FUSE says 50+ operators already run peptide brands on it, with 1,200+ programs launched and a 94% refill retention rate. That last number is the tell, because peptides live and die on subscriptions, and FUSE is engineered for repeat revenue instead of one-off visits. You can see the purpose-built version on its peptide telehealth page.

How do the two platforms stack up side by side?

Here's the quick read before we go deeper. Everything in this table comes from each company's own current pages.

Which one is built for peptides, really?

FUSE vs MyOrbitHealth - Which one is built for peptides

This is the question most operators are actually asking when they land on a MyOrbitHealth alternatives search. MyOrbit handles peptides, no argument there, they're one vertical inside a long list. FUSE treats peptides as the entire product. The intake asks the questions a peptide program needs, the catalog is stocked with the treatments these brands sell (semaglutide, tirzepatide, NAD+, sermorelin, testosterone, and the rest), and fulfillment routes through compounding pharmacies that are LegitScript certified and PCAB accredited.

Worth noticing. Here's a detail that shows where each company's head is at. On its own pricing page, MyOrbit cites a competitor's published rates (Telegra at $3,000 to $6,000 a month) to make a point about hidden fees, yet still doesn't post its own number. FUSE just prints the number.

So if your growth plan is one hero treatment turning into a recurring subscription, the peptide-first build is quietly doing work that a general platform would leave on your plate. For the full mechanics, FUSE walks through it on its how it works page.

Which platform is more upfront about pricing?

This is where the two genuinely part ways, and it's the reason a lot of operators make the switch. FUSE posts three plans on its pricing page with no sales call required. MyOrbit's pricing page explains its model clearly and fairly, with a flat platform fee, 0% medication markup, no revenue share, and you as the merchant of record, but it stops short of a dollar figure. You find out what you'll actually pay after you book a demo.

Plan	What you pay	Who it's for
FUSE DIY	$0 to build, then $499/mo + 3% fee	Hands-on operators who self-serve
FUSE Growth (Recommended)	$5,600 upfront, then $699/mo + 2% fee	Teams who want guided onboarding
FUSE Partner	$30,000 onboarding, then $3,000/mo	Done-for-you premium brand builds
MyOrbitHealth	Scoped quote after a demo	Multi-vertical clinics needing custom scope

FUSE's merchant service fee runs 3% on DIY and 2% on Growth and Partner. MyOrbit counters with a 0% medication markup and no exit fee, which is a genuine point in its favor at high volume. The honest move either way, and MyOrbit's own site says this too, is to model everything down to cost per active patient per month before you sign anything.

How fast can you actually go live?

Both say "days." FUSE puts harder numbers on it and lets you start without talking to anyone first.

Build free before you commit. FUSE lets you design your brand and set up products at $0, then pay only once you flip it live.
Self-serve or guided. Start solo on DIY, or let the FUSE team run your go-live on Growth and Partner.
Partner brands can launch in as little as 3 days once your materials and pharmacy are ready.
AI-assisted setup. FUSE's AI connector lets you configure your store by talking to an assistant instead of wiring up an API.
MyOrbit starts with a demo, then scopes your build across verticals, states, and volume.

To be fair to MyOrbit, its developer-first REST API is strong if you have engineers and want a deep custom integration. FUSE's AI-and-templates approach gets a non-technical operator live faster.

What about compliance, providers, and labs?

Credit where it's due, this is MyOrbit's strongest column. To keep things honest, here's where each one leads.

If you need SOC 2 Type II on paper today, broad lab draws, insurance billing, or a native app across many specialties, MyOrbit has the wider surface. For a cash-pay peptide brand, FUSE's LegitScript plus 503A/503B sourcing covers what the model genuinely requires.

Keep in mind. LegitScript certification is what lets you advertise a telehealth brand on Google and Meta at all, so both platforms building it in matters more than it first sounds. FUSE breaks down the cost and timeline in its LegitScript guide.

So should you switch to FUSE?

It depends on what you're building, and we'll keep it straight. Go with MyOrbit if you're standing up a multi-specialty clinic, want lab and insurance rails, and don't mind a sales call to get your number. Go with FUSE if you're launching a focused peptide, GLP-1, or longevity brand and you want transparent pricing, a free build to test first, peptide-tuned workflows, and a path to live that doesn't start with a scoped quote.

You see the price before you talk to anyone.
The whole stack is built for how peptides sell, down to intake, refills, and compounding supply.
You can build free and launch from $499 a month, with no upfront commitment.
94% refill retention across 1,200+ programs says the subscription model holds.

Weighing other MyOrbitHealth alternatives?

MyOrbit and FUSE aren't the only names in white-label telehealth, and if you're comparison-shopping it's worth seeing how FUSE lines up against the rest. FUSE runs the same side-by-side, sourced from public pages, against OpenLoop (which MyOrbit also compares itself to) and against Karpa Health. If a peptide brand is the goal, the fastest way to decide is to see the platform yourself.

References

Daniel Meursing

CEO

Daniel is a two-time founder who has scaled service businesses across major U.S. markets. A Y Combinator competition winner, he focuses on removing operational and regulatory barriers so operators can build and scale modern healthcare businesses.

Background: Startup Operations & Service Systems
Experience: 2x Founder, Multi-Market U.S. Scaling
Qualifications: Healthtech Market Expertise & Operational Scaling
Key Achievement: Scaled Premier Staff & Eventstaff across major U.S. markets

Frequently Asked Questions

Is FUSE a direct alternative to MyOrbitHealth?

For a focused peptide, GLP-1 or longevity brand, yes. Both are white-label platforms that let you run a licensed clinic under your own brand with no medical license. They split on focus and pricing: FUSE is peptide-native and publishes its rates, while MyOrbit runs a broader multi-specialty platform and quotes you after a demo.

How much does each platform cost?

FUSE publishes three plans: DIY, free to build and $499 a month once live; Growth, $5,600 upfront then $699 a month; and Partner, $30,000 onboarding then $3,000 a month. MyOrbit doesn't post a list price. It charges a flat platform fee scoped to your verticals, states and volume, which you get after booking a demo.

Do I need a medical license to run a program on either one?

No. Both FUSE and MyOrbit state that operators don't need a medical license. Licensed providers in each network review every intake and write every prescription. Your side is brand, marketing and customer acquisition, and the clinical decision always sits with the reviewing provider.

Which platform is better for a peptide or GLP-1 brand?

FUSE, in most cases. MyOrbit lists peptides as one of 38+ specialties, while FUSE is built around them, with peptide-tuned intake, a catalog covering semaglutide, tirzepatide, NAD+ and more, and 503A/503B compounding pharmacy sourcing. If peptides and GLP-1 are your whole business, the peptide-native build does more of the work for you.

Can I switch to FUSE and keep my patients and data?

Yes. FUSE runs the clinical infrastructure while you own the brand, the storefront and the customer relationship. MyOrbit similarly lets you own your patients and data with export anytime. Moving between them keeps your brand and audience intact; what changes is the pricing and clinical model underneath.

FUSE vs MyOrbitHealth: Which White-Label Platform Fits Your Program